Navigation Links
BioMarin Announces Third Quarter 2011 Financial Results
Date:10/27/2011

: Initiation of Phase II trial for BMN-111 for Achondroplasia
4Q 2013: Anticipated regulatory approval of GALNS for MPS IVA

Research and Development ProgramsBioMarin continues to make significant investments in research and development to ensure persistent growth for the company.  The current pipeline includes programs in various stages of development that are focused on treating a range of serious unmet medical needs.  BioMarin will host an R&D Day on Thursday, December 8th in New York to discuss its clinical and preclinical pipeline in detail.Advanced Clinical Programs

  • GALNS for MPS IVA: BioMarin is enrolling patients in a randomized, double-blind, placebo-controlled Phase III study with primary endpoint of six-minute walk distance.  The study will be 24 weeks in treatment duration with treatment doses of two mg/kg/week and two mg/kg/every other week.  The company expects to enroll approximately 160 patients across 40 centers worldwide and is on track to report top-line results in the second half of 2012.  
  • Kuvan Outcomes Study: PKU-016, a randomized, placebo-controlled, 13-week Kuvan outcomes study is ongoing.  Endpoints include clinically validated measures of neuropsychiatric symptoms and, if successful, may enable a label amendment.  The company expects to report top-line results in the second half of 2012.
  • Firdapse: The Phase III trial for LEMS for FDA approval in the U.S. is ongoing.

  • Mid-Stage Clinical Programs

  • PEG-PAL for PKU: The company will provide an update on the Phase II study at the R&D Day in December.  The company expects to initiate a Phase III trial in the second half of 2012.
  • Hand-Held Blood Phe Monitor: Regulatory clearance and commercial availability of the handheld blood Phe monitor are expected in the second half of 2013.

  • Early-Stage Clinical Programs

  • BMN
    '/>"/>

  • SOURCE BioMarin Pharmaceutical Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. BioMarin to Present at the UBS Global Life Sciences Conference
    2. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
    3. BioMarin to Present at the Baird Health Care Conference
    4. BioMarin to Present at the Wedbush Life Sciences Conference
    5. BioMarin Announces Second Quarter 2011 Financial Results
    6. BioMarin to Host Second Quarter 2011 Financial Results Conference Call and Webcast on Thursday, July 28 at 5:00 p.m. ET
    7. BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
    8. BioMarin to Present at the William Blair Growth Stock Conference
    9. BioMarin to Present at the Jefferies Global Healthcare Conference
    10. BioMarin to Present at the Bank of America Merrill Lynch Healthcare Conference
    11. BioMarin Announces First Quarter 2011 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/3/2015)...  Four financial reasons to reduce pressure ulcers ... by Leaf Healthcare, Inc . According ... (AHRQ), pressure ulcers cost the US healthcare ... addition to direct treatment related costs, pressure ulcers ... impact hospital performance metrics. On top of the ...
    (Date:9/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) ... on China Olmesartan Market, 2010-2019" report to their ... successfully developed by Sankyo Pharmaceuticals Co., Ltd and was ... was approved by FDA to enter the American market ... drug in the world after it succeeded in the ...
    (Date:9/3/2015)... Sep. 03, 2015 Research ... of the "Investigation Report on China,s Bromhexine Market, ... air pollution worsens, the incidence of respiratory disease keeps ... drugs. Bromhexine, a semisynthetic derivative of vasicine, is a ... and asthma associated with viscid or excessive mucus. It ...
    Breaking Medicine Technology:Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 2Four Financial Reasons to Reduce Pressure Ulcer Incidents: Leaf Healthcare Releases White Paper on Direct and Indirect Costs Associated with Pressure Ulcers 3China Olmesartan Investigation Market Report 2010-2019 2China Bromhexine Market Report 2015-2019 2
    (Date:9/3/2015)... ... September 03, 2015 , ... For ... in its Annual Inc. 5000 list of fastest-growing private companies in America. ... fraction of the nation's companies have demonstrated such remarkably consistent high growth, particularly ...
    (Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... Dr. Robert ... of Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July ... Winchell is a nationally renowned expert in care for the critically injured and the ...
    (Date:9/3/2015)... ... 03, 2015 , ... As a result of the Patient ... health insurance plans, more employers are moving to a self-funded model for pharmacy ... 2014 United Benefit Advisors (UBA) Health Plan Survey. , UBA’s survey, the nation’s ...
    (Date:9/3/2015)... ... September 03, 2015 , ... Hunters Creek Retrievers is again ... champion AKC Black Lab Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 ... to enjoy Thanksgiving and Christmas with an extra big smile. , This adorable ...
    (Date:9/3/2015)... ... September 03, 2015 , ... “We wish to ... impact the delicate life balance between work and leisure to the benefit of ... Leaptrott, CEO , A LifeMinder Plus® Emergency Care Document Set duly executed set ...
    Breaking Medicine News(10 mins):Health News:Inc. 5000 Includes Intellicure, Inc., Two Years in a Row 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 2Health News:LifeMinder Plus® Announces Emergency Care Document Set Giveaway for America 3
    ... that target specific molecular mechanisms of cancer have improved the ... may come with a cost to the patient,s sex life, ... European Society for Medical Oncology (ESMO) in Milan, Italy, French ... the impact of cancer therapy on the sexual functioning of ...
    ... national leader in the development and implementation of electronic ... to the prestigious Institute of Medicine of the National ... the forefront of policy, standards, financing and expansion of ... improve patient care delivery and safety. He is director ...
    ... Medicine researchers have found that a gene associated with the ... levels in people with Alzheimer,s disease. The research, led by ... Neurology, and Professor of Psychiatry and Geriatrics and Adult Development ... in Aging Cell . The new study ...
    ... Ohio Scientists have found that a synthetic molecule they ... cells, halting a process that allows some of those cancer ... this gene,s function, certain liver cancer cells appear to be ... the oncogene, called STAT3, prevents a protein from protecting the ...
    ... drug has shown an impressive ability to prevent disease ... with advanced disease, investigators reported at the 35th Congress ... Preliminary results from an ongoing Phase-II trial of the ... patients whose cancers harbor mutated forms of the EGFR ...
    ... young people who are diagnosed with bone cancer could benefit ... at The University of Nottingham. The Bone Cancer Research ... a new project at the University which is testing a ... cancer cells. Researchers at the School of Clinical Sciences, ...
    Cached Medicine News:Health News:Sexual issues a major concern for cancer patients taking new targeted drugs 2Health News:J. Marc Overhage elected to Institute of Medicine 2Health News:Diabetes gene linked to degeneration of enzyme involved in Alzheimer's disease onset and progression 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 2Health News:Blocking an oncogene in liver cancer could be potential therapy option 3Health News:New Phase II study shows first-line promise of lung cancer drug PF-299 2Health News:Hope for a new treatment for bone cancer 2
    Double bent ends prevent wire from catching when pushed forward. Designed for use with the Castroviejo Snare (E3675). Package of 12 stainless steel wires. Overall length 4.3 inches....
    Open ring design for globe fixation during various ocular procedures. Blunt fixation points. Swivel handle provides increased flexibility. Manufactured in titanium....
    Open ring design for globe fixation during various ocular procedures. Blunt fixation points. Swivel handle provides increased flexibility. Manufactured in titanium....
    Open 14 mm fixation ring with teeth to prevent damage to conjuctiva. Gauge is marked every 10 degrees to determine the extent of the arc to be incised. Two broad marks align with steep axis....
    Medicine Products: